PhD
Helen has over 10 years of experience in the pharmaceutical industry focused on predictive and mechanistic toxicology. She has expertise in early project toxicology gained through roles in discovery safety and safety pharmacology, supporting projects across multiple therapy areas. Helen has a passion for collaborative working and applying the latest technology to toxicology.
Sean holds a PhD in immuno-pharmacology from the University of Liverpool, focused on developing experimental and conceptual means to address T-cell mediated hypersensitivity reactions. He has long-standing links with drug safety research at Liverpool where he received the Syngenta prize for Pharmacology at degree level and where he maintains an academic profile. He has several publications focused on the immuno-toxicological aspects of small molecular weight compounds and immune-checkpoint inhibitors. Sean particularly values working with inter-disciplinary experts to drive rational, data-led decision making in drug development projects.
Read more about Dr Sean Hammond
Angela has a strong scientific background in chemistry, pharmacology and toxicology and over 30 years of regulatory affairs experience in medicinal product and medical device development. She has extensive experience of ICH, FDA and Committee for Medicinal Products for Human Use (CHMP) guidelines for a wide range of pharmaceutical products, and the International Organization for Standardization (ISO) standards for medical devices, in vitro diagnostics and quality systems. She has been influential in regulatory affairs training and mentoring and is a Fellow of The Organisation for Professionals in Regulatory Affairs (TOPRA) and a Fellow of the Royal Society of Chemistry. Angela was the winner of the 2015 TOPRA Award for Contribution and 2020 TOPRA Award for Inspiration. Angela’s knowledge, breadth of experience in regulatory affairs, toxicology and pharmacology abilities and strategic approach aligns with and supports the toxicology group in ApconiX.
Karen is a Medical Writer with extensive experience in communicating health economics and outcomes research (HEOR) through a range of market access materials. Having worked within a global contract research organisation, she has a track record of delivering high quality, evidence-based materials to clients from across the pharmaceutical industry (from the top ten global pharmaceutical companies to small biotechnology companies) and across multiple disease areas, including infectious diseases and inflammatory disorders, cancer and rare genetic disorders. Karen has a comprehensive understanding of the core needs and challenges in gaining drug reimbursement and enjoys using her broad scientific knowledge to provide solutions to these challenges.
James is an experienced and innovative toxicologist having worked for over 20 years in the pharmaceutical industry with AstraZeneca and as an independent consultant. As a molecular-investigative toxicologist he helped resolve safety issues for a wide range of drug discovery and development projects across the major therapy areas. He has also developed advanced in vitro models for organ toxicity screening, pioneered the application of novel technology and informatics platforms and has a strong track record of delivering Target Safety Assessments. James (also known as Sid) has a real interest in solving mechanisms of drug toxicity and is energised by working collaboratively in industry, academic and commercial settings.
Read more here
Simon is a European Registered Toxicologist and Diplomate of the American Board of Toxicology with over 15 years of nonclinical and toxicology experience within various pharmaceutical and medical device settings. Simon has worked within biotech and a number of CROs across a diverse range of therapeutic areas in both Discovery and Development. His experience includes a variety of therapeutic platforms including small molecules, biologicals, and medical devices. During his career, he has acted as a single point of contact for the planning and monitoring outsourced studies, interpretation of study results, contingency planning/troubleshooting, report reviewing and authoring of regulatory documents. Simon’s knowledge, breadth of experience and pragmatic approach aligns perfectly with the toxicologist group in ApconiX as we support our growing client base.
Read more here
Duncan is an expert pharmacologist with an international reputation in secondary and safety pharmacology, gained over 18 years in drug discovery and development at AstraZeneca and Novartis. Having worked with project teams at all stages of discovery and development across multiple therapy areas, he has a track record of optimising small molecule off-target safety profiles and in understanding and interpreting target-related safety risks. Duncan enjoys bringing his passion for pharmacology to successful collaborative teams.
Read more here
Laurence is an experienced DMPK and toxicological Scientist, with 20 years of non-clinical drug development and chemical experience at medium and large CROs as well as within AstraZeneca. Specialising in Business Development for the last 13 years Laurence combines a passion for appropriate pharmaceutical development and a knowledge of project scientific and commercial needs. he is well placed to support both our customers and Apconix to best deliver non-clinical safety programmes. Laurence has a proven track record for communication, ownership, integrity and delivery, building mutually beneficial and lasting customer relationships.
Read more here
Kemal is a toxicologist with 20 years’ experience supporting biopharma projects from early discovery through clinical development. He has experience across different therapeutic areas, target classes, and modalities (small molecule and biologics) and has worked in both small biotech and large pharma organisations. Kemal has a track record of delivering timely, fit-for-purpose toxicology data packages, on budget and successfully devising and executing critical path risk mitigation strategies
